Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Magicell
Taipei, Taiwanmedigen.com.tw ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Magicell-NK has been approved for use in Taiwan in several hospitals for cancer therapy; currently in Phase 1/2 trials for multiple solid tumor indications including post-surgery pancreatic duct adenocarcinoma, cholangiocarcinoma, and colon cancer.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyNK cell therapy
- Industry
- Biotech
02
Partnerships
NKure Therapeutics (India) for Magicell-NK licensing and development in IndiaTaipei Municipal Wanfang Hospital (Taiwan) for collaborative clinical projectsGya Biotechnology, Xiu Chuan Hospital (Taiwan) for cell therapy delivery
Beyond the preview
Go deeper on Magicell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Magicell.